ProJuvant™ (Pluronic F127®/chitosan) enhances the immune response to intranasally administered tetanus toxoid

Th immune response induced byH pylorivaccine with chitosan as adjuvant and its relation to immune protection

“…Following a light centrifugation (50 r/min, 10 min), small particles in the supernatants were removed, filtered through a 400/2800 stainless steel mesh, and further centrifuged to collect the particles at 1400 r/min for 10 min as previously described [9] . Preparation of chitosan solution Deacetylated (88.5%) chitosan stock solution was prepared at 3% (w/w) in 0.8% (v/v) acetic acid 0.9% (w/v) saline and heated at 37℃ to dissolve [10] .…”

Novel Mucoadhesive Polymers for Nasal Drug Delivery

“…In certain disease conditions the sequence of glycoproteins is altered. This altered state can be used as a target by complementary amino acid sequences by attaching them to a drug delivery device [66]. Antibodies can be produced against selected molecules present on mucosal surfaces.…”

“…Due to their high specificity, antibodies can be a rational choice as a polymeric ligand for designing site-specific mucoadhesives. This approach can be useful for targeting drugs to tumour tissues [66] or even normal cells.…”

B cell mediated priming following pneumococcal colonization

“…To determine the amount of bacterial nasopharyngeal colonization post-mortem nasal washes were performed by injecting 300 μl of a solution containing 5mM EDTA, 0.5% gelatin, and 0.05% Tween 20 in PBS retrograde via the trachea into the nasopharynx [15]. The resulting lavage fluid was collected at the nostrils.…”